Comparison of the Bupropion versus Aripiprazole Adjunctive Therapy for the Treatment of Female Depression : Post-Hoc Analyses from a Randomized Prospective Open-Label Multi-Center Study
- Author:
Mu sung KEUM
1
;
Eun Jin CHEON
;
Kwang Hun LEE
;
Bon Hoon KOO
;
Young Ji LEE
;
Young Woo PARK
;
Jong hun LEE
;
Seung Jae LEE
;
Hyung Mo SUNG
Author Information
1. Department of Psychiatry, Yeungnam University College of Medicine, Yeungnam University Medical Center, Daegu, Korea. annemyanne@hanmail.net
- Publication Type:Multicenter Study
- Keywords:
Aripiprazole;
Bupropion;
Treatment resistant depression;
Female depression;
Anxiety;
Somatic symptom
- MeSH:
Anxiety;
Aripiprazole;
Bupropion;
Depression;
Depressive Disorder, Major;
Depressive Disorder, Treatment-Resistant;
Fatigue;
Female;
Humans;
Iowa;
Prospective Studies;
Sleep Initiation and Maintenance Disorders;
Weights and Measures
- From:
Mood and Emotion
2018;16(3):140-151
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The purpose of this study was to examine effects of adjunctive aripiprazole versus bupropion, on depressive symptoms of female depression.METHODS: Sixty six female patients with major depressive disorders were enrolled from a six-week, randomized prospective open-label multi-center study. Participants were randomized to receive aripiprazole (2.5–10 mg/day) or bupropion (150–300 mg/day). Montgomery Asberg Depression Rating Scale, 17-item Hamilton Depression Rating scale (HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales (anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms.RESULTS: Overall, both treatments improved depressive symptoms, without causing serious adverse events. There were significant differences in the HAM-D17 total score (p=0.046) and CGI-S (p=0.004), between aripiprazole and bupropion augmentation, favoring aripiprazole over bupropion. Aripiprazole revealed significantly greater effect size in depressed mood (p=0.006), retardation (p=0.005), anxiety psychic (p=0.032), and general somatic symptom (p=0.01).CONCLUSION: While both treatments were effective, results of this study suggested that aripiprazole may be preferable, in treating general and core symptoms of female depression.
